Legend Capital, a subsidiary of Legend Holdings Ltd., was founded in April 2001 and is based in Beijing, China. The firm manages private equity investments across four funds, totaling up to US$700 million, focusing primarily on early-stage ventures and mid-market growth companies. Its investment strategy targets sectors including information technology, telecommunications, media, healthcare, consumer goods, clean technology, and advanced manufacturing, with a strong emphasis on businesses that are either based in China or related to Chinese markets. Legend Capital is known for its active involvement with portfolio companies, providing them with essential business resources and tailored services to enhance development and optimize company performance in the Chinese market. The firm has built a diverse portfolio of over 60 companies, contributing to its reputation as a respected player in China's venture capital industry.
MacroLux operates as a medical technology company focusing on endoscopic interventional business. MacroLux develops endoscopic interventional therapy solutions and promote them to the majority of medical customers.
ClinChoice, also known as Fountain Medical Development Ltd, is a contract research organization based in Beijing, China. The company specializes in providing comprehensive, ICH GCP compliant clinical research services to multinational clients in both China and the United States. Its offerings include consulting, project management, regulatory affairs, and clinical operations, as well as central laboratory services. ClinChoice also focuses on site management, biometrics, and designing clinical trials. Additional services encompass the collection, review, assessment, and reporting of adverse events and serious adverse events, along with data and safety monitoring board handling and signal detection services. Founded in 2006, ClinChoice has established itself as a key player in the clinical research sector.
Reliable Med is a developer and provider of clinical mass spectrometry equipment designed for in vitro diagnostic (IVD) tests. The company focuses on addressing the needs of the medical industry by offering high-end clinical mass spectrometry devices and IVD detection kits. By doing so, Reliable Med aims to enhance the efficiency and accuracy of patient diagnoses within the healthcare sector.
Medilink Therapeutics
Series B in 2022
MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.
Lunit Inc. is a South Korean company that specializes in developing advanced algorithms for medical image analysis and general object detection using machine learning technology. The firm focuses on areas such as digital chest X-ray, digital mammography, digital pathology, and fundus photography. By leveraging cutting-edge deep learning techniques, Lunit aims to assist physicians in making accurate and efficient clinical decisions. The company has demonstrated its expertise in image recognition, having ranked among the top five in the ImageNet Challenge, a prominent competition in the field. Lunit's technology is notable for its ability to utilize weakly labeled data, enhancing its pattern recognition capabilities. Supported by significant venture capital investments, Lunit is actively engaged in large-scale research collaborations with major university hospitals in South Korea, reflecting its strong reception within the medical community.
Developer of minimally invasive ventricular assist devices. The company's products with advantages of small trauma, large auxiliary flow, and easy to use, providing a circulation improvement plan that doctors can use conveniently and patients can afford.
HC Scientific Technology Co., Ltd. is a company based in Chengdu, China, that specializes in the development, manufacturing, and distribution of genetic testing instruments, reagents, and software. Founded in 2015, the company serves various sectors, including clinical molecular diagnostics, health genetic testing, and agricultural molecular breeding, both domestically and internationally. HC Scientific's product lineup features instruments such as the Matrix Arrayer for reaction plate preparation, the Matrix Cycler for thermal cycling, and the Matrix Scanner for fluorescence detection. Additionally, the company provides consumables like the Matrix plate and Matrix Mix genotyping reagents, along with a data management system known as Matrix Master. Committed to innovation, HC Scientific focuses on autonomous research and development of its intellectual property, aiming to deliver high-throughput, automated, and cost-effective genetic testing solutions.
Berry Oncology is a medical technology company focused on enhancing cancer prevention and diagnosis through advanced genomic testing solutions. The company offers a range of products and services, including genetic diagnosis, companion diagnostics, and tools for monitoring treatment response and prognosis prediction for various malignant tumors. By addressing clinical challenges associated with cancer detection and management, Berry Oncology aims to facilitate early diagnosis and treatment, ultimately improving patient quality of life and reducing cancer risks. Its mission emphasizes precise treatment for all patients, while its vision seeks to establish the company as a leader in early screening and diagnosis within the global market, particularly in China's tumor gene testing sector.
Reliable Med is a developer and provider of clinical mass spectrometry equipment designed for in vitro diagnostic (IVD) tests. The company focuses on addressing the needs of the medical industry by offering high-end clinical mass spectrometry devices and IVD detection kits. By doing so, Reliable Med aims to enhance the efficiency and accuracy of patient diagnoses within the healthcare sector.
MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.
Beijing Genskey Technology Co., Ltd. is a medical diagnostic service provider specializing in genetic testing. Founded in 2007 and headquartered in Beijing, China, the company employs high-throughput sequencing technology combined with intelligent algorithm analysis to enhance pathogen diagnosis. Genskey aims to address common challenges in the medical diagnostics field, such as low detection rates, lengthy processes, and accuracy issues. By improving the timeliness and precision of diagnostic results, Genskey seeks to ensure that patients suffering from severe infections receive prompt and accurate diagnoses, ultimately contributing to better health outcomes.
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases, particularly through immuno-oncology. Established in 2016 and headquartered in Shanghai, China, the company employs two patented transgenic mouse platforms for generating fully human monoclonal antibodies and heavy chain only antibodies, enabling the creation of bispecific antibodies and other therapeutic compounds. Harbour BioMed's development pipeline includes products targeting various conditions, such as autoimmune diseases and respiratory infections. The company also licenses its antibody platforms to other firms and academic institutions via its Harbour Antibodies subsidiary. It has formed strategic collaborations with several notable organizations, including The Wistar Institute and WuXi Biologics, and maintains partnerships with various biopharmaceutical companies. With operations in Cambridge, Massachusetts, and antibody platform innovation in Rotterdam, the Netherlands, Harbour BioMed is positioned to enhance drug discovery and development across multiple global markets.
Beijing Genskey Technology Co., Ltd. is a medical diagnostic service provider specializing in genetic testing. Founded in 2007 and headquartered in Beijing, China, the company employs high-throughput sequencing technology combined with intelligent algorithm analysis to enhance pathogen diagnosis. Genskey aims to address common challenges in the medical diagnostics field, such as low detection rates, lengthy processes, and accuracy issues. By improving the timeliness and precision of diagnostic results, Genskey seeks to ensure that patients suffering from severe infections receive prompt and accurate diagnoses, ultimately contributing to better health outcomes.
Lunit Inc. is a South Korean company that specializes in developing advanced algorithms for medical image analysis and general object detection using machine learning technology. The firm focuses on areas such as digital chest X-ray, digital mammography, digital pathology, and fundus photography. By leveraging cutting-edge deep learning techniques, Lunit aims to assist physicians in making accurate and efficient clinical decisions. The company has demonstrated its expertise in image recognition, having ranked among the top five in the ImageNet Challenge, a prominent competition in the field. Lunit's technology is notable for its ability to utilize weakly labeled data, enhancing its pattern recognition capabilities. Supported by significant venture capital investments, Lunit is actively engaged in large-scale research collaborations with major university hospitals in South Korea, reflecting its strong reception within the medical community.
dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.
Provider of integrated oral medical solutions for oral health and dental industry. The company offers technical training, operation and management consulting services to their clients. The company also involves in the design, development, manufacturing, and sales of oral medical equipment, providing a full fledged ecosystem for the dental and oral health industry.
Beijing Deepwise Science And Technology Co., Ltd. develops an artificial intelligence (AI) based medical application software that provides clinical imaging analysis and clinical diagnostics. The company offers early screening and diagnosis of various malignant diseases. It serves to hospitals, medical centers, and third party imaging centers. The company was founded in 2017 and is based in Beijing, China.
New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.
Beijing Genskey Technology Co., Ltd. is a medical diagnostic service provider specializing in genetic testing. Founded in 2007 and headquartered in Beijing, China, the company employs high-throughput sequencing technology combined with intelligent algorithm analysis to enhance pathogen diagnosis. Genskey aims to address common challenges in the medical diagnostics field, such as low detection rates, lengthy processes, and accuracy issues. By improving the timeliness and precision of diagnostic results, Genskey seeks to ensure that patients suffering from severe infections receive prompt and accurate diagnoses, ultimately contributing to better health outcomes.
SAFE Pharmaceutical, officially known as Beijing Saifu Medical Research Institute Co., Ltd., operates as a Contract Research Organization (CRO) specializing in pharmaceutical research and development services. The company collaborates with esteemed institutions such as the Shanghai Institute of Materia Medica and the National Drug Safety Evaluation and Research Center, leveraging their expertise to enhance its operational capabilities. With a core team comprised of experienced researchers from prestigious scientific organizations, SAFE Pharmaceutical offers comprehensive services that include R&D consulting, toxicology evaluations, and clinical trial design. This integrated approach allows pharmaceutical developers to efficiently advance their product research and development initiatives, supported by strong technical expertise and management experience in drug development and GLP compliance.
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases, particularly through immuno-oncology. Established in 2016 and headquartered in Shanghai, China, the company employs two patented transgenic mouse platforms for generating fully human monoclonal antibodies and heavy chain only antibodies, enabling the creation of bispecific antibodies and other therapeutic compounds. Harbour BioMed's development pipeline includes products targeting various conditions, such as autoimmune diseases and respiratory infections. The company also licenses its antibody platforms to other firms and academic institutions via its Harbour Antibodies subsidiary. It has formed strategic collaborations with several notable organizations, including The Wistar Institute and WuXi Biologics, and maintains partnerships with various biopharmaceutical companies. With operations in Cambridge, Massachusetts, and antibody platform innovation in Rotterdam, the Netherlands, Harbour BioMed is positioned to enhance drug discovery and development across multiple global markets.
Urotronic, Inc. is a medical device company based in Plymouth, Minnesota, founded in 2014. The company specializes in developing innovative solutions for urology, particularly in the treatment of urethral blockages. Its flagship product, Optilume, is a drug-coated balloon catheter designed to treat urethral strictures in men. This device combines balloon dilation with localized drug delivery, utilizing the drug paclitaxel to inhibit cell proliferation and reduce the formation of scar tissue that can lead to stricture recurrence. By effectively covering the affected area during the procedure, Optilume offers a low-cost, minimally-invasive treatment option for patients suffering from urinary tract conditions, catering primarily to urologists and their patients.
China Diagnostic Medical Corporation (CDMC)
Private Equity Round in 2018
China Diagnostic Medical Corporation is a diagnostic testing reagents maker.
Beijing Chemclin Biotech Co., Ltd. specializes in the development, production, and sales of diagnostic reagents and instruments for clinical use. Founded in 1999 and based in Beijing, China, the company focuses on in-vitro diagnostics, offering a range of products including reagents for infectious diseases, tumor markers, and thyroid and diabetes testing. Chemclin also provides semi-automated and fully automated chemiluminescent analyzers, which facilitate the performance of chemiluminescent assays. Additionally, the company offers commercial testing services for various health conditions, including liver fibrosis and fertility. As a subsidiary of China Diagnostics Medical Corporation, Chemclin is committed to delivering innovative diagnostic solutions and services to the Chinese healthcare market.
Lunit Inc. is a South Korean company that specializes in developing advanced algorithms for medical image analysis and general object detection using machine learning technology. The firm focuses on areas such as digital chest X-ray, digital mammography, digital pathology, and fundus photography. By leveraging cutting-edge deep learning techniques, Lunit aims to assist physicians in making accurate and efficient clinical decisions. The company has demonstrated its expertise in image recognition, having ranked among the top five in the ImageNet Challenge, a prominent competition in the field. Lunit's technology is notable for its ability to utilize weakly labeled data, enhancing its pattern recognition capabilities. Supported by significant venture capital investments, Lunit is actively engaged in large-scale research collaborations with major university hospitals in South Korea, reflecting its strong reception within the medical community.
Puyi (Shanghai) Biotechnology Co., Ltd. is a Shanghai-based company founded in 2012 that specializes in the research and development of implantable medical devices, primarily for Ear-Nose-Throat (ENT) applications. The company focuses on high-value medical devices, emphasizing material science and drug delivery technology. Puyi has developed minimally-invasive, degradable sinus stents that release medication, significantly improving patient outcomes after surgery. In addition to ENT, the company has expanded its expertise into reproductive health and medical aesthetics, establishing a unique position in the medical device market.
Yosemite Clinic is a multidisciplinary medical center located in Central Pudong, Shanghai, offering a wide range of walk-in services in a modern and well-equipped environment. The clinic provides specialties including family medicine, internal medicine, gynecology, pediatrics, rehabilitation, sports medicine, dentistry, ophthalmology, dermatology, and medical cosmetology. It is particularly noted for its focus on Minimally Invasive Surgery and Ambulatory Surgery. The facility is equipped with advanced medical imaging technology, including CT, X-ray, and ultrasound, alongside a fully operational laboratory and pharmacy. The clinic's diverse team of healthcare professionals hails from both China and around the world, allowing them to offer services in multiple languages such as English, Japanese, Malay, Mandarin Chinese, and Cantonese, ensuring comprehensive care for a diverse patient population.
Beijing Deepwise Science And Technology Co., Ltd. develops an artificial intelligence (AI) based medical application software that provides clinical imaging analysis and clinical diagnostics. The company offers early screening and diagnosis of various malignant diseases. It serves to hospitals, medical centers, and third party imaging centers. The company was founded in 2017 and is based in Beijing, China.
Kunya Medical is a medical equipment service company based in Shanghai, China, founded in 2009. The company specializes in the maintenance and servicing of imaging and radiation equipment, offering comprehensive management solutions for hospitals. Kunya Medical provides a range of services, including overall hosting of medical equipment, technical maintenance, installation, debugging, and equipment relocation. Additionally, the company supplies spare parts and equipment management software, catering to both domestic and international brands of large and medium-sized medical devices. By offering these services, Kunya Medical aims to enhance the management of medical equipment in hospitals and extend the operational lifespan of clinical devices.
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases, particularly through immuno-oncology. Established in 2016 and headquartered in Shanghai, China, the company employs two patented transgenic mouse platforms for generating fully human monoclonal antibodies and heavy chain only antibodies, enabling the creation of bispecific antibodies and other therapeutic compounds. Harbour BioMed's development pipeline includes products targeting various conditions, such as autoimmune diseases and respiratory infections. The company also licenses its antibody platforms to other firms and academic institutions via its Harbour Antibodies subsidiary. It has formed strategic collaborations with several notable organizations, including The Wistar Institute and WuXi Biologics, and maintains partnerships with various biopharmaceutical companies. With operations in Cambridge, Massachusetts, and antibody platform innovation in Rotterdam, the Netherlands, Harbour BioMed is positioned to enhance drug discovery and development across multiple global markets.
Berry Oncology is a medical technology company focused on enhancing cancer prevention and diagnosis through advanced genomic testing solutions. The company offers a range of products and services, including genetic diagnosis, companion diagnostics, and tools for monitoring treatment response and prognosis prediction for various malignant tumors. By addressing clinical challenges associated with cancer detection and management, Berry Oncology aims to facilitate early diagnosis and treatment, ultimately improving patient quality of life and reducing cancer risks. Its mission emphasizes precise treatment for all patients, while its vision seeks to establish the company as a leader in early screening and diagnosis within the global market, particularly in China's tumor gene testing sector.
Ayshealth Technology develops chronic disease management system. It offers Guideline-based Decision Support (GDS) that assists and guides assist physicians and other health service providers with cloud services and professional medical support. The company was founded in 2014 and is based in Beijing, China
New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.
PhiSkin is a skin and laser clinic located in China, specializing in a range of skin care treatments. The clinic offers services that utilize advanced laser technology and skin care techniques to address various skin concerns. By focusing on effective and innovative solutions, PhiSkin aims to enhance the overall skin health and appearance of its clients.
Qiang Sen International Community Medical (QSICM) operates community healthcare service centers. The Clinic offers internal medicine, pediatrics, gynecology, stomatology, laboratory, ultrasonography, and electrocardiography services. QSICM serves patients in China.
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases, particularly through immuno-oncology. Established in 2016 and headquartered in Shanghai, China, the company employs two patented transgenic mouse platforms for generating fully human monoclonal antibodies and heavy chain only antibodies, enabling the creation of bispecific antibodies and other therapeutic compounds. Harbour BioMed's development pipeline includes products targeting various conditions, such as autoimmune diseases and respiratory infections. The company also licenses its antibody platforms to other firms and academic institutions via its Harbour Antibodies subsidiary. It has formed strategic collaborations with several notable organizations, including The Wistar Institute and WuXi Biologics, and maintains partnerships with various biopharmaceutical companies. With operations in Cambridge, Massachusetts, and antibody platform innovation in Rotterdam, the Netherlands, Harbour BioMed is positioned to enhance drug discovery and development across multiple global markets.
Operator of a neurology clinic. The clinic specializes in neurosurgery, brain tumor treatment and epilepsy treatment, enabling patients to obtain expert, specialized care.
Qiang Sen International Community Medical (QSICM) operates community healthcare service centers. The Clinic offers internal medicine, pediatrics, gynecology, stomatology, laboratory, ultrasonography, and electrocardiography services. QSICM serves patients in China.
New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.
ET Healthcare, Inc. is an in vitro diagnostics company that specializes in manufacturing central laboratory analyzers for both inpatient and outpatient testing in various medical settings, including hospitals and clinics. The company has developed the Pylon Immunochemistry System, an integrated turnkey solution that addresses the immunodiagnostics needs across several areas, such as inflammation, cardiac function, fertility, infectious diseases, and tumors. Additionally, the Pylon BNP Immunoassay aids in managing heart failure by measuring B-type natriuretic peptide levels in plasma. ET Healthcare’s offerings include a variety of immunoassays for cardiac markers, blood clots, and other health conditions, facilitating simplified blood analysis for physicians. Based in Palo Alto, California, the company also has offices in Shanghai, China, and operates manufacturing facilities in Suzhou, China.
Beijing Percans Oncology Research Co., Ltd. is a medical service provider focused on delivering personalized treatment plans for cancer patients. Based in Beijing, China, the company specializes in developing innovative cancer-specific drug products, particularly in the areas of synthetic lethality and immunotherapy. By tailoring treatment strategies to the unique needs of each patient, Percans Oncology aims to enhance the effectiveness of cancer therapies, ultimately helping to extend and improve patients' lives.
Developer and supplier of a full range of in vitro diagnostic(IVD) equipment designed to improve clinical decision making and treatment pathways. The company's products include chemistry analyzer and PCR analyzer using microfluidics technology, providing medical industry with efficient IVD tests and reduced healthcare spending.
LenoMed Medical is a medical equipment manufacturer based in Shanghai, China, established in 2014. The company specializes in the development and production of insulin pumps, drug infusion pumps, and related disposables, including the InnoTech insulin pump and infusion sets. With over 15 years of research and development experience in infusion technology, LenoMed is focused on advancing diabetes management through innovative solutions. The company is exploring the integration of continuous glucose monitoring (CGM) technology with insulin pumps to create a closed-loop system, enhancing diabetes care management. LenoMed has formed a strategic alliance with The Pharma Partners to further its objectives in this sector.
ET Healthcare, Inc. is an in vitro diagnostics company that specializes in manufacturing central laboratory analyzers for both inpatient and outpatient testing in various medical settings, including hospitals and clinics. The company has developed the Pylon Immunochemistry System, an integrated turnkey solution that addresses the immunodiagnostics needs across several areas, such as inflammation, cardiac function, fertility, infectious diseases, and tumors. Additionally, the Pylon BNP Immunoassay aids in managing heart failure by measuring B-type natriuretic peptide levels in plasma. ET Healthcare’s offerings include a variety of immunoassays for cardiac markers, blood clots, and other health conditions, facilitating simplified blood analysis for physicians. Based in Palo Alto, California, the company also has offices in Shanghai, China, and operates manufacturing facilities in Suzhou, China.
DXY is a social media platform focused on the pharmaceuticals and life sciences sectors, facilitating communication among healthcare professionals and the public. Founded by Li Tiantian in July 2000 and headquartered in Hangzhou, China, DXY serves over three million registered members. The platform features informative articles on the latest research and general health advice, promoting knowledge exchange among physicians and life science professionals. Additionally, DXY offers precision digital marketing services and public health resources online, aimed at enhancing user productivity and engagement within the healthcare community.
ET Healthcare, Inc. is an in vitro diagnostics company that specializes in manufacturing central laboratory analyzers for both inpatient and outpatient testing in various medical settings, including hospitals and clinics. The company has developed the Pylon Immunochemistry System, an integrated turnkey solution that addresses the immunodiagnostics needs across several areas, such as inflammation, cardiac function, fertility, infectious diseases, and tumors. Additionally, the Pylon BNP Immunoassay aids in managing heart failure by measuring B-type natriuretic peptide levels in plasma. ET Healthcare’s offerings include a variety of immunoassays for cardiac markers, blood clots, and other health conditions, facilitating simplified blood analysis for physicians. Based in Palo Alto, California, the company also has offices in Shanghai, China, and operates manufacturing facilities in Suzhou, China.
EverCare (Beijing) Holding Group Co., Ltd. is a prominent operator of cosmetic and plastic surgery hospitals in Beijing, China. Established in 1997, the company specializes in a wide range of medical and aesthetic services, including various cosmetic plastic surgeries such as facial and breast procedures, as well as gender-specific surgeries. Additionally, it offers laser treatments for skin rejuvenation, hair removal, and other dermatological concerns. EverCare also provides comprehensive services including medical hair restoration, cosmetic stomatology, weight loss programs, aesthetic injections, and gynecological treatments. The company emphasizes personalized patient care by delivering one-on-one private medical and beauty treatment services, ensuring that clients receive safe and effective solutions tailored to their needs. Through its diverse offerings, EverCare aims to enhance the beauty and health of its patients while maintaining a commitment to quality and safety.
CareRay Digital Medical Technology Co Ltd specializes in the development and production of advanced flat panel detectors for digital X-ray imaging systems. Their products are utilized across various sectors, including medical, veterinary, security, and industrial applications. CareRay's extensive product portfolio encompasses a range of imaging solutions such as radiography, mammography, fluoroscopy, and dental imaging, along with various associated accessories. The company is committed to innovation, aiming to enhance diagnostic capabilities through the latest technological advancements in imaging.
CareRay Digital Medical Technology Co Ltd specializes in the development and production of advanced flat panel detectors for digital X-ray imaging systems. Their products are utilized across various sectors, including medical, veterinary, security, and industrial applications. CareRay's extensive product portfolio encompasses a range of imaging solutions such as radiography, mammography, fluoroscopy, and dental imaging, along with various associated accessories. The company is committed to innovation, aiming to enhance diagnostic capabilities through the latest technological advancements in imaging.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.